Literature DB >> 12528605

Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment.

John J Murray1, Robert A Nathan, Edwin A Bronsky, Abayomi O Olufade, Douglass Chapman, Benjamin Kramer.   

Abstract

Improvement in patient daily functioning and well-being resulting from disease-related symptom relief is increasingly viewed as a clinically relevant therapeutic outcome. The objective of this study was to evaluate the health-related quality of life (HRQL) effects, safety and efficacy of cetirizine in the treatment of seasonal allergic rhinitis, and impact on self-reported work/school-related productivity and activity impairment (WPAI). This was a double-blind, placebo-controlled, parallel-group study. Adult patients (n = 865) were randomized to daily treatment for 2 weeks with cetirizine or placebo. Patient disease-specific HRQL and WPAI were assessed at baseline and weeks 1 and 2 of treatment using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Allergy-Specific Work Productivity and Activity Impairment (WPAI-AS) Instrument, respectively. Treatment with cetirizine resulted in greater (p < 0.001) improvement in overall RQLQ and individual domain scores (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, emotional), as compared with placebo. Cetirizine therapy produced a 28.9% mean reduction in total symptom severity complex (TSSC) score versus 12.7% with placebo at study end. Work/school productivity and activity impairment were significantly (p < 0.001) decreased from baseline for cetirizine-treated patients compared with placebo. The incidence of treatment-related side effects was similar between groups. Cetirizine provides safe and effective symptomatic relief in adults with SAR while significantly improving HRQL and providing a positive impact on work/school-related productivity and activity impairment. These results provide a more comprehensive assessment of cetirizine, indicating that its benefits extend beyond conventional measures of clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12528605

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  6 in total

Review 1.  Hay fever in adolescents and adults.

Authors:  Aziz Sheikh; Sukhmeet Singh Panesar; Sarah Salvilla; Sangeeta Dhami
Journal:  BMJ Clin Evid       Date:  2009-11-18

Review 2.  Congestion and sleep impairment in allergic rhinitis.

Authors:  Timothy J Craig; Amir Sherkat; Sahar Safaee
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Selecting the optimal oral antihistamine for patients with allergic rhinitis.

Authors:  Jeffrey M Lehman; Michael S Blaiss
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.

Authors:  Michael N Fein; David A Fischer; Andrew W O'Keefe; Gord L Sussman
Journal:  Allergy Asthma Clin Immunol       Date:  2019-10-01       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.